Hofseth BioCare ASA (OSL: HBC)
Norway
· Delayed Price · Currency is NOK 2.020
-0.030 (-1.46%)
Aug 30, 2024, 4:25 PM CET
Hofseth BioCare ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 219.8 | 190.82 | 119.13 | 76.88 | 52.51 | 67.78 | Upgrade
|
| Other Revenue | 10.28 | 27.7 | 1.32 | 10.74 | 16.74 | - | Upgrade
|
| Revenue | 230.08 | 218.51 | 120.45 | 87.62 | 69.25 | 67.78 | Upgrade
|
| Revenue Growth (YoY) | 24.35% | 81.42% | 37.47% | 26.52% | 2.17% | 11.59% | Upgrade
|
| Cost of Revenue | 171.57 | 165 | 102.49 | 77.05 | 39.53 | 72.35 | Upgrade
|
| Gross Profit | 58.51 | 53.51 | 17.96 | 10.57 | 29.72 | -4.57 | Upgrade
|
| Selling, General & Admin | 80.43 | 76.25 | 76.03 | 60.35 | 42.64 | 34.49 | Upgrade
|
| Other Operating Expenses | 52.22 | 43.38 | 40.13 | 39.43 | 52.33 | 13.06 | Upgrade
|
| Operating Expenses | 170.73 | 156.04 | 146.39 | 129.13 | 121.74 | 75 | Upgrade
|
| Operating Income | -112.22 | -102.53 | -128.43 | -118.56 | -92.02 | -79.57 | Upgrade
|
| Interest Expense | -9.58 | -7.54 | -9.95 | -9.39 | -9.22 | -8.57 | Upgrade
|
| Interest & Investment Income | 0.56 | 0.55 | 0.65 | 0.61 | 0.55 | 0.51 | Upgrade
|
| Earnings From Equity Investments | -0.1 | 2.54 | -0.2 | 0.03 | -0.78 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.16 | 0.3 | 0.74 | 0.91 | -0.54 | -0.81 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | - | -0.06 | -0.09 | -0.78 | Upgrade
|
| EBT Excluding Unusual Items | -121.18 | -106.68 | -137.2 | -126.46 | -102.09 | -89.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0 | Upgrade
|
| Asset Writedown | - | - | -0.19 | - | - | - | Upgrade
|
| Pretax Income | -121.18 | -106.68 | -137.39 | -126.46 | -102.09 | -89.22 | Upgrade
|
| Earnings From Continuing Operations | -121.18 | -106.68 | -137.39 | -126.46 | -102.09 | -89.22 | Upgrade
|
| Minority Interest in Earnings | 0 | 0 | 0 | 0 | 0 | 0.01 | Upgrade
|
| Net Income | -121.18 | -106.68 | -137.39 | -126.46 | -102.09 | -89.21 | Upgrade
|
| Net Income to Common | -121.18 | -106.68 | -137.39 | -126.46 | -102.09 | -89.21 | Upgrade
|
| Shares Outstanding (Basic) | 403 | 395 | 375 | 358 | 334 | 306 | Upgrade
|
| Shares Outstanding (Diluted) | 403 | 395 | 375 | 358 | 334 | 306 | Upgrade
|
| Shares Change (YoY) | 2.43% | 5.43% | 4.72% | 7.25% | 8.95% | 18.65% | Upgrade
|
| EPS (Basic) | -0.30 | -0.27 | -0.37 | -0.35 | -0.31 | -0.29 | Upgrade
|
| EPS (Diluted) | -0.30 | -0.27 | -0.37 | -0.35 | -0.31 | -0.29 | Upgrade
|
| Free Cash Flow | -26.39 | -5.43 | -49.19 | -84.7 | -94.21 | -41.34 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.01 | -0.13 | -0.24 | -0.28 | -0.13 | Upgrade
|
| Gross Margin | 25.43% | 24.49% | 14.91% | 12.06% | 42.92% | -6.74% | Upgrade
|
| Operating Margin | -48.77% | -46.92% | -106.63% | -135.32% | -132.88% | -117.40% | Upgrade
|
| Profit Margin | -52.67% | -48.82% | -114.06% | -144.34% | -147.42% | -131.62% | Upgrade
|
| Free Cash Flow Margin | -11.47% | -2.49% | -40.84% | -96.68% | -136.04% | -60.99% | Upgrade
|
| EBITDA | -97.86 | -89.83 | -118.46 | -104.57 | -79 | -61.65 | Upgrade
|
| EBITDA Margin | -42.53% | -41.11% | -98.35% | -119.35% | -114.08% | -90.96% | Upgrade
|
| D&A For EBITDA | 14.37 | 12.7 | 9.97 | 14 | 13.02 | 17.92 | Upgrade
|
| EBIT | -112.22 | -102.53 | -128.43 | -118.56 | -92.02 | -79.57 | Upgrade
|
| EBIT Margin | -48.77% | -46.92% | -106.63% | -135.32% | -132.88% | -117.40% | Upgrade
|
| Revenue as Reported | 230.08 | 218.51 | 120.45 | 87.62 | 69.25 | 67.78 | Upgrade
|
| Advertising Expenses | - | 13.49 | 15.04 | 13.03 | 7.86 | 4.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.